Study: Toxic Exposure in Pregnancy May Drive Disease Risk Across Generations
New research shows a single toxic exposure during pregnancy may drive disease risk across generations, highlighting emerging opportunities for clinical labs to leverage epigenetic biomarkers for earlier, preventative diagnostics.
A new study from Washington State University suggests that a single exposure to a toxic fungicide during pregnancy may influence disease risk for up to 20 generations, with implications for how clinical laboratories understand chronic disease and prevention strategies.
Published in the Proceedings of the National Academy of Sciences, the research builds on decades of work in epigenetics led by Michael Skinner, a pioneer in the study of transgenerational inheritance.
Epigenetic Inheritance Expands the Diagnostic Timeline
The study found that exposure to vinclozolin—a fungicide commonly used in agriculture—triggered disease patterns in rats that persisted for 20 generations. Notably, disease incidence not only continued but worsened in later generations, with severe reproductive complications emerging.
“This study really does say that this is not going to go away,” Skinner said. “We need to do something about it. We can use epigenetics to move us away from reactionary medicine and toward preventative medicine.” (Photo credit: Washington State University)
For clinical laboratories, these findings show a growing shift toward understanding disease not just as an immediate or genetic condition, but as one influenced by ancestral environmental exposures.
Germline Changes Drive Long-Term Risk
Unlike traditional toxicology models, the study highlights how disease risk is transmitted through epigenetic changes in germline cells—sperm and eggs—rather than direct exposure alone.
“Essentially, when a gestating female is exposed, the fetus is exposed,” Skinner explained. “And then the germline inside the fetus is also exposed… Once it’s programmed in the germline, it’s as stable as a genetic mutation.”
This mechanism suggests that clinical labs may need to consider multi-generational risk factors when interpreting biomarkers or assessing patient risk profiles.
Disease Burden Intensifies Over Generations
While disease prevalence remained relatively stable across early generations, researchers observed a sharp increase in severity beginning around the 15th generation.
“By the 16th, 17th, 18th generations, disease became very prominent and we started to see abnormalities during the birth process,” Skinner noted. “Either the mother would die, or all the pups would die, so it was a really lethal sort of pathology.”
These findings suggest that long-term population health trends—such as rising chronic disease rates—may have roots in historical environmental exposures.
Implications for Clinical Laboratories
The research aligns with broader epidemiological trends showing increased rates of chronic diseases, including cancer and cardiovascular conditions. According to the CDC, more than three-quarters of Americans now live with at least one chronic disease.
For laboratories, the study underscores the potential value of epigenetic biomarkers in predicting disease susceptibility well before clinical symptoms appear.
Moving Toward Preventative Diagnostics
As clinical laboratories continue to expand their role in precision medicine, epigenetic testing may offer a pathway to earlier intervention and improved patient outcomes.
By identifying individuals at elevated risk decades in advance, labs could support a shift toward preventative care models—helping clinicians intervene before disease onset rather than reacting after diagnosis.
For lab leaders and pathologists, the study highlights that diagnostics may soon extend beyond the individual patient to include inherited environmental risk factors spanning generations.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
—Janette Wider
